ID   ALMC-2
AC   CVCL_M526
SY   ALMC2
DR   Wikidata; Q54749244
RX   CelloPub=CLPUB00604;
RX   DOI=10.1182/blood.V112.11.2732.2732;
RX   PubMed=18567838;
RX   PubMed=23992230;
RX   PubMed=24013424;
RX   PubMed=25015330;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Characteristics: Produces IgG lambda.
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Established from a patient suffering from primary systemic amyloidosis which relapsed with multiple myeloma.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M525 ! ALMC-1
SX   Female
AG   50Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 14
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1182/blood.V112.11.2732.2732;
RA   Keats J.J., Arendt B.K., Braggio E., Barrett M.T., Price-Troska T.L.,
RA   Fonseca R., Bergsagel P.L., Jelinek D.F.;
RT   "Comparison of multiple myeloma donor patient samples and derived cell
RT   lines identifies a confirmed hyperdiploid myeloma cell line and
RT   demonstrates remarkable genetic similarity between cell lines and
RT   patient samples.";
RL   Blood 112 Suppl. 1:2732a-2732a(2008).
//
RX   PubMed=18567838; DOI=10.1182/blood-2008-03-143040;
RA   Arendt B.K., Ramirez-Alvarado M., Sikkink L.A., Keats J.J.,
RA   Ahmann G.J., Dispenzieri A., Fonseca R., Ketterling R.P.,
RA   Knudson R.A., Mulvihill E.M., Tschumper R.C., Wu X.-S., Zeldenrust S.R.,
RA   Jelinek D.F.;
RT   "Biologic and genetic characterization of the novel amyloidogenic
RT   lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.";
RL   Blood 112:1931-1941(2008).
//
RX   PubMed=23992230; DOI=10.1111/ejh.12192;
RA   Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.;
RT   "Responsiveness of cytogenetically discrete human myeloma cell lines
RT   to lenalidomide: lack of correlation with cereblon and interferon
RT   regulatory factor 4 expression levels.";
RL   Eur. J. Haematol. 91:504-513(2013).
//
RX   PubMed=24013424; DOI=10.4161/cc.26193;
RA   Walters D.K., Arendt B.K., Jelinek D.F.;
RT   "CD147 regulates the expression of MCT1 and lactate export in multiple
RT   myeloma cells.";
RL   Cell Cycle 12:3175-3183(2013).
//
RX   PubMed=25015330; DOI=10.18632/oncotarget.2159;
RA   Arendt B.K., Walters D.K., Wu X., Tschumper R.C., Jelinek D.F.;
RT   "Multiple myeloma cell-derived microvesicles are enriched in CD147
RT   expression and enhance tumor cell proliferation.";
RL   Oncotarget 5:5686-5699(2014).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//